EGRP News Flash - November 14, 2012

NCI Reissues RFAs for Innovative Molecular Analysis Technologies Program

The National Cancer Institute has reissued four Requests for Applications (RFAs) under the Innovative Molecular Analysis Technologies (IMAT) for Cancer Program. The Program focuses on stimulating and accelerating the development, integration, maturation, and dissemination of the most novel and highly innovative technologies in support of cancer research and medicine.

Its goal is to develop tools and methods that enable cancer researchers to make new discoveries, enhance our understanding of cancer etiology and proliferation, improve detection capabilities, develop diagnostic methods and treatment strategies, conduct large population studies, address and reduce disparities in clinical cancer, and assist in clinical decision-making.

The RFAs are:

  1. Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research - Exploratory/Developmental Research Grant Award (R21) - which supports research projects centered on the inception and preliminary development of highly innovative molecular analysis technologies with potentially high impact on cancer research.

    NIH Guide for Grants and Contracts: RFA-CA-13-001

    Letters of intent are due January 20, 2013; April 20, 2013; and August 20, 2013. Applications are due February 20, 2013; May 20, 2013; and September 20, 2013, by 5:00 p.m. local time of applicant organization.

  2. Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research - Exploratory/Developmental Grants Phase II Awards (R33)

    NIH Guide for Grants and Contracts: RFA-CA-13-002

    Letters of intent are due January 20, 2013; April 20, 2013; and August 20, 2013. Applications are due February 20, 2013; May 20, 2013; and September 20, 2013, by 5:00 p.m. local time of applicant organization.

  3. Early-Stage Development of Innovative Technologies for Biospecimen Science - Exploratory/Developmental Research Grant Award (R21)

    NIH Guide for Grants and Contracts: RFA-CA-13-003

    Letters of intent are due January 20, 2013; April 20, 2013; and August 20, 2013. Applications are due February 20, 2013; May 20, 2013; and September 20, 2013, by 5:00 p.m. local time of applicant organization.

  4. Validation and Advanced Development of Emerging Technologies for Biospecimen Science - Exploratory/Developmental Grants Phase II Awards (R33)

    NIH Guide for Grants and Contracts: RFA-CA-13-004

    Letters of intent are due January 20, 2013; April 20, 2013; and August 20, 2013. Applications are due February 20, 2013; May 20, 2013; and September 20, 2013, by 5:00 p.m. local time of applicant organization.

These RFAs expire September 21, 2013.

Access the IMAT ProgramExternal Web Site Policy.

For cancer epidemiology questions related to the RFAs described above, contact the Epidemiology and Genomics Research Program's (EGRP) Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch (MTB); or Rao L. Divi, Ph.D., Program Director, MTB.

Return to Top